




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

ARCA biopharma Inc. Rank 31 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

ARCA biopharma Inc. Rank 31 of 50



The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 653% points. The greatest weakness of ARCA biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 153% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	54,421
Assets, Non-Current	455
General and Administrative Expense	5,503
Goodwill	0
Liabilities Hidden Reserves	0
Liabilities, Current	3,498
Liabilities, Non-Current	383
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property, Plant and Equipment, Net	48
Research and Development	13,832
Revenues	13

Output Variable	Value in 1000 USD
Liabilities	3,881
Assets	54,924
Expenses	19,335
Market Value Liabilities	3,881
Market Value Assets	54,924
Stockholders Equity	51,043
Net Income	-19,322
Comprehensive Net Income	-19,322
Economic Capital Ratio	-76%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai